Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows
low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this
study is to compare the efficacy and tolerability of two different regimens of low doses
rituximab for the treatment of adult patients with ITP.